Search
Selected Filter
Displaying 291–300 of 541 news results
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Researchers Identify Regions in the Retina to Target Therapies for Certain RP Patients
Research NewsUniversity of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
-
In the Press
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
-
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing vision loss
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
Research NewsThe company is also expanding its Phase ½ trial for the emerging treatment
-
Foundation News
Accepting grant applications for advancing retinal degeneration treatments toward human studies
-
Research News
A Phase 3 trial for the treatment is planned
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
Research NewsThe goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Research NewsTreatment combines gene therapy and a device that generates and delivers retinal code
-
Foundation Fighting Blindness to Host Virtual VISIONS 2020 Conference
Foundation NewsThe national conference will be held virtually on June 25-27, providing the latest in science and research, practical adapting and thriving, and an opportunity to connect with others who are visually impaired.
